Nonresponse to treatment for hepatitis C

Current management strategies

He Jun Yuan, William M. Lee

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Chronic hepatitis C affects >170 million people worldwide, causing cirrhosis and liver cancer in a sizeable proportion of patients. Substantial progress has been made in the treatment of chronic hepatitis C. More than 50% of patients can achieve sustained virological response after 24-48 weeks of interferon and ribavirin combination therapy, making chronic hepatitis C a potentially curable disease. However, a large proportion of patients with chronic hepatitis C do not clear the virus after current standard therapy. Hepatitis C virus develops two pathways to counteract the antiviral effect of interferon. Some chronic hepatitis C patients may have a virus that is more resistant to interferon therapy, while other patients appear to have defective immune responses or poor tolerance or compliance to interferon-based antiviral therapy. The possible strategies to improve antiviral efficiency in these nonresponders are to increase the dosage, prolong the duration of treatment and improve the compliance of patients. A total of 6-15% of prior nonresponders to standard interferon plus ribavirin therapy will respond to re-treatment with peginterferon plus ribavirin, while 32-50% of patients who have relapsed will respond to re-treatment. New small molecules are under development to treat chronic hepatitis C and may be important particularly in the treatment of prior nonresponders to current standard therapy.

Original languageEnglish (US)
Pages (from-to)27-42
Number of pages16
JournalDrugs
Volume68
Issue number1
StatePublished - 2008

Fingerprint

Hepatitis C
Interferons
Ribavirin
Viruses
Chronic Hepatitis C
Antiviral Agents
Therapeutics
Liver
Molecules
Liver Neoplasms
Patient Compliance
Hepacivirus
Fibrosis

Keywords

  • Boceprevir, therapeutic use
  • Ciluprevir, therapeutic use
  • Hepatitis C, treatment
  • Interferon alfacon 1, therapeutic use
  • Merimepodib, therapeutic use
  • Peginterferon alfa 2a, therapeutic use
  • Peginterferon alfa 2b, therapeutic use
  • Research and development

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Nonresponse to treatment for hepatitis C : Current management strategies. / Yuan, He Jun; Lee, William M.

In: Drugs, Vol. 68, No. 1, 2008, p. 27-42.

Research output: Contribution to journalArticle

@article{c7f80af4780d4c369cde8f06f23c2014,
title = "Nonresponse to treatment for hepatitis C: Current management strategies",
abstract = "Chronic hepatitis C affects >170 million people worldwide, causing cirrhosis and liver cancer in a sizeable proportion of patients. Substantial progress has been made in the treatment of chronic hepatitis C. More than 50{\%} of patients can achieve sustained virological response after 24-48 weeks of interferon and ribavirin combination therapy, making chronic hepatitis C a potentially curable disease. However, a large proportion of patients with chronic hepatitis C do not clear the virus after current standard therapy. Hepatitis C virus develops two pathways to counteract the antiviral effect of interferon. Some chronic hepatitis C patients may have a virus that is more resistant to interferon therapy, while other patients appear to have defective immune responses or poor tolerance or compliance to interferon-based antiviral therapy. The possible strategies to improve antiviral efficiency in these nonresponders are to increase the dosage, prolong the duration of treatment and improve the compliance of patients. A total of 6-15{\%} of prior nonresponders to standard interferon plus ribavirin therapy will respond to re-treatment with peginterferon plus ribavirin, while 32-50{\%} of patients who have relapsed will respond to re-treatment. New small molecules are under development to treat chronic hepatitis C and may be important particularly in the treatment of prior nonresponders to current standard therapy.",
keywords = "Boceprevir, therapeutic use, Ciluprevir, therapeutic use, Hepatitis C, treatment, Interferon alfacon 1, therapeutic use, Merimepodib, therapeutic use, Peginterferon alfa 2a, therapeutic use, Peginterferon alfa 2b, therapeutic use, Research and development",
author = "Yuan, {He Jun} and Lee, {William M.}",
year = "2008",
language = "English (US)",
volume = "68",
pages = "27--42",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Nonresponse to treatment for hepatitis C

T2 - Current management strategies

AU - Yuan, He Jun

AU - Lee, William M.

PY - 2008

Y1 - 2008

N2 - Chronic hepatitis C affects >170 million people worldwide, causing cirrhosis and liver cancer in a sizeable proportion of patients. Substantial progress has been made in the treatment of chronic hepatitis C. More than 50% of patients can achieve sustained virological response after 24-48 weeks of interferon and ribavirin combination therapy, making chronic hepatitis C a potentially curable disease. However, a large proportion of patients with chronic hepatitis C do not clear the virus after current standard therapy. Hepatitis C virus develops two pathways to counteract the antiviral effect of interferon. Some chronic hepatitis C patients may have a virus that is more resistant to interferon therapy, while other patients appear to have defective immune responses or poor tolerance or compliance to interferon-based antiviral therapy. The possible strategies to improve antiviral efficiency in these nonresponders are to increase the dosage, prolong the duration of treatment and improve the compliance of patients. A total of 6-15% of prior nonresponders to standard interferon plus ribavirin therapy will respond to re-treatment with peginterferon plus ribavirin, while 32-50% of patients who have relapsed will respond to re-treatment. New small molecules are under development to treat chronic hepatitis C and may be important particularly in the treatment of prior nonresponders to current standard therapy.

AB - Chronic hepatitis C affects >170 million people worldwide, causing cirrhosis and liver cancer in a sizeable proportion of patients. Substantial progress has been made in the treatment of chronic hepatitis C. More than 50% of patients can achieve sustained virological response after 24-48 weeks of interferon and ribavirin combination therapy, making chronic hepatitis C a potentially curable disease. However, a large proportion of patients with chronic hepatitis C do not clear the virus after current standard therapy. Hepatitis C virus develops two pathways to counteract the antiviral effect of interferon. Some chronic hepatitis C patients may have a virus that is more resistant to interferon therapy, while other patients appear to have defective immune responses or poor tolerance or compliance to interferon-based antiviral therapy. The possible strategies to improve antiviral efficiency in these nonresponders are to increase the dosage, prolong the duration of treatment and improve the compliance of patients. A total of 6-15% of prior nonresponders to standard interferon plus ribavirin therapy will respond to re-treatment with peginterferon plus ribavirin, while 32-50% of patients who have relapsed will respond to re-treatment. New small molecules are under development to treat chronic hepatitis C and may be important particularly in the treatment of prior nonresponders to current standard therapy.

KW - Boceprevir, therapeutic use

KW - Ciluprevir, therapeutic use

KW - Hepatitis C, treatment

KW - Interferon alfacon 1, therapeutic use

KW - Merimepodib, therapeutic use

KW - Peginterferon alfa 2a, therapeutic use

KW - Peginterferon alfa 2b, therapeutic use

KW - Research and development

UR - http://www.scopus.com/inward/record.url?scp=37249082661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249082661&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 27

EP - 42

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 1

ER -